Dr Petranel Ferrao has extensive experience in the translational research area of cancer therapies. She completed her PhD from the University of Adelaide for research on “The individual and co-operative effects of the c-MYB and c-KIT oncogenes in murine haemopietic cells”; conducted at the Division of Haematology, Hanson Centre for Cancer Research, Adelaide.
She focussed her early post-doctoral training on translational projects investigating mechanisms of drug resistance to conventional chemotherapeutics and new targeted therapeutics for the treatment of leukaemia. As a Brawn Research Fellow at the University of Newcastle, her team reported on the response and resistance of various KIT mutants to the targeted therapeutic drug Imatinib (Glivec). Their early findings on this work contributed to advancing the clinical development of KIT inhibitor drugs for the treatment of KIT-driven malignancies such as GIST. She gained additional tertiary teaching and commercial experience with a start-up venture, while on a break from academic research. Dr Ferrao has built upon her early post-doctoral expertise in drug resistance, targeted therapies, receptor tyrosine kinases and signalling, to establish several translational projects on identifying predictors/biomarkers of treatment response for patient stratification and determining ways to overcome treatment resistance in melanoma, ovarian cancer, colorectal cancer, lung cancer, pancreatic cancer and various haematological malignancies. Her longer term research vision is to improve therapy outcomes and patient survival rates by utilising novel predictors/biomarkers to define the most optimal treatment strategies for use in a personalised and precision manner.
Find out more about Petranel Ferrao's experience
Petranel Ferrao's highlights
Petranel Ferrao's selected work
Utilising A Novel Predictor To Stratify Patients With Therapy-Resistant Pancreatic Cancer ..
Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Thera..
Overcoming Receptor Tyrosine Kinase Mediated Resistance To Braf Inhibitors In Metastatic M..
Displaying the 3 most recent projects by Petranel Ferrao.
Displaying the 6 most recent scholarly works by Petranel Ferrao.
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale, Robert N Jorissen, Frederic Z Li, Sheren Al-Obaidi, Teresa Ward, Karen E Sheppard, Patricia E Bukczynska, Richard J Young, Samantha E Boyle, Mark Shackleton, Gideon Bollag, Georgina V Long, Eugene Tulchinsky, Helen Rizos, Richard B Pearson, Grant A McArthur, Amardeep S Dhillon, Petranel T Ferrao
Journal article | 2015 | Science Signaling
Surgery - Austin Health
Bachelor of Science
Bachelor of Science (Honours, first class)
Doctor of Philosophy